RXRX Stock Price Today (July 2026) — Recursion Pharmaceuticals, Inc. Analysis & Key Metrics 2026-07-17
Recursion Pharmaceuticals, Inc. (RXRX) is trading at $2.94, down 2.48% today (as of July 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $6.64 (125.6% upside).
- Volatility remains elevated (56.01% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (-56.10% YoY) alongside significant competitive pressures.
RXRX Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Recursion Pharmaceuticals, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $1.36B
P/E Ratio
Forward P/E: -4.18
Revenue Growth
Year over Year
Analyst Target
+125.6% upside potential
Key Investor Questions About RXRX
What investors need to know before buying
Based on current market data, RXRX presents a oversold technical setup with challenging fundamentals.
- Technicals say: Oversold (RSI 28.72)
- Fundamentals say: Challenging (declining revenue trends)
RXRX's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for RXRX investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $72.38M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, RXRX stock traded between $2.77 and $7.18—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 56.01% annualized volatility and β=2.57, the stock exhibits high sensitivity to market moves—making RXRX suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.34, indicating a +1.21% shift from the previous trading day.
Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy?
Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock.
2 Beaten-Down Stocks That Still Aren't Worth Buying
Your hard-earned money would be better spent elsewhere.
Is Recursion Pharmaceuticals (RXRX) The Best Penny Stocks According to Billioanires?
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best Penny Stocks to Invest In According to Billionaires. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotechnology company that is building an AI-native discovery platform to industrialize drug discovery. Although still in the clinical stage, the company generates much of its revenue from key partnerships and collaborations with […]
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.72, moving 3.13% from the previous trading session.
Recursion Pharmaceuticals (RXRX) Is Up 8.0% After Russell Index Additions Expand Its Investor Base – Has The Bull Case Changed?
In late June 2026, Recursion Pharmaceuticals, Inc. was added to multiple Russell value and small-cap benchmarks, including the Russell 2000 Value Index, expanding its presence in key equity indices. This index inclusion comes as Recursion’s AI‑native drug discovery platform and recent clinical and data‑driven milestones increasingly draw interest from large investors and collaborators. We’ll now examine how this broader index inclusion, alongside Recursion’s AI‑driven discovery progress,...
Recursion Pharmaceuticals (RXRX) Stock Looks Fully Valued Despite AI Drug Hopes
Recursion Pharmaceuticals has been trying to rebuild momentum after a steep five year decline in shareholder returns, yet its current checks still point to a stock that screens as expensive rather than clearly cheap. Over the past 5 years, Recursion Pharmaceuticals shareholders have seen the stock decline about 90%, which puts extra focus on whether recent optimism is supported by today’s valuation. Progress with the AI driven drug discovery platform and clinical data for REC-4881 can...
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Two stocks that have fallen out of favor and one hot stock that was one of Thursday's biggest losers were on the Ark Invest founder's shopping list.
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, and industry partnerships.
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?
Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.
Frequently Asked Questions
Common investor questions about Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (RXRX) is currently trading at $2.94. The RSI (14-day) is at 28.7, indicating oversold territory (potentially undervalued). Wall Street analysts have a consensus "Hold" recommendation. The mean analyst price target of $6.64 implies 125.6% upside from current levels. Volatility is high at 56.0% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Recursion Pharmaceuticals, Inc. (RXRX): The trailing P/E ratio is -2.54, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is -4.18, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is 1.53. Price-to-Sales is 23.27. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 7 analysts covering RXRX, the consensus price target is $6.64. This represents a 125.6% upside from the current price of $2.94. The range spans from a low target of $3.00 to a high target of $10.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "Hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Recursion Pharmaceuticals, Inc. (RXRX) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Recursion Pharmaceuticals, Inc. (RXRX) investors include: 1. High volatility (56.0% annualized)—the stock can experience significant daily price swings. 2. Declining revenue (-56.1% YoY), indicating potential business headwinds. 3. Elevated short interest (36.8% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Recursion Pharmaceuticals, Inc.'s (RXRX) current debt and financial health profile: Total debt stands at $72.38M. The debt-to-equity ratio is 7.06, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 5.47, indicating strong short-term liquidity. The quick ratio is 5.15. The company holds $654.47M in cash and equivalents. Free cash flow is negative at $-177,795,632, which could limit the company's ability to manage debt obligations.